Cargando…

Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2’,2’‐difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer

The aim of this work is to build a mechanistic multiscale pharmacokinetic model for the anticancer drug 2’,2’‐difluorodeoxycytidine (gemcitabine, dFdC), able to describe the concentrations of dFdC metabolites in the pancreatic tumor tissue in dependence of physiological and genetic patient character...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia‐Cremades, Maria, Melillo, Nicola, Troconiz, Iñaki F., Magni, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214642/ https://www.ncbi.nlm.nih.gov/pubmed/32043298 http://dx.doi.org/10.1111/cts.12747

Ejemplares similares

Kinetics of mouse jejunum radiosensitization by 2′,2′-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells
Publicado: (1998)

Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.
por: GrÃ©goire, V., et al.
Publicado: (1997)

Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2′, 2′-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity()()
por: Naguib, Youssef W., et al.
Publicado: (2016)

Enteric reabsorption processes and their impact on drug pharmacokinetics
por: Ibarra, Manuel, et al.
Publicado: (2021)

Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells
por: Papa, Anne-Laure, et al.
Publicado: (2012)

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
por: Fraunhoffer, Nicolas Alejandro, et al.
Publicado: (2022)

Gemcitabine-incorporated polyurethane films for controlled release of an anticancer drug
por: Choi, Seong Hoon, et al.
Publicado: (2019)

NUC041, a Prodrug of the DNA Methytransferase Inhibitor 5-aza-2′,2′-Difluorodeoxycytidine (NUC013), Leads to Tumor Regression in a Model of Non-Small Cell Lung Cancer
por: Daifuku, Richard, et al.
Publicado: (2018)

A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention
por: Jayachandran, Priya, et al.
Publicado: (2021)

Genotypes Affecting the Pharmacokinetics of Anticancer Drugs
por: Bertholee, Daphne, et al.
Publicado: (2016)

Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo
por: Chen, Ya-Hui, et al.
Publicado: (2020)

Mechanistic and multiscale aspects of thermo-catalytic CO(2) conversion to C(1) products
por: Alam, Md. Imteyaz, et al.
Publicado: (2021)

Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer
por: Nakata, Bunzo, et al.
Publicado: (2010)

A predictive pharmacokinetic–pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination
por: Terranova, Nadia, et al.
Publicado: (2013)

A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 2—Model Applications
por: Chen, X, et al.
Publicado: (2014)

Multiscale Approach to Investigate Self-Assembly of Telodendrimer Based Nanocarriers for Anticancer Drug Delivery
por: Jiang, Wenjuan, et al.
Publicado: (2014)

Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties
por: Hong, Sungwoo, et al.
Publicado: (2018)

Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer
por: Huang, Jun-Hao, et al.
Publicado: (2023)

Pharmacokinetics of Peptide Mediated Delivery of Anticancer Drug Ellipticine
por: Ma, Weina, et al.
Publicado: (2012)

Pharmacokinetic Imaging with Radiolabeled Molecularly Targeted Anticancer Drugs
por: Bauer, Martin, et al.
Publicado: (2020)

Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells
por: Nishikubo, Kou, et al.
Publicado: (2023)

Multiscale Tumor Modeling With Drug Pharmacokinetic and Pharmacodynamic Profile Using Stochastic Hybrid System
por: Oduola, Wasiu Opeyemi, et al.
Publicado: (2018)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
por: Zhou, Yunjiang, et al.
Publicado: (2019)

Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer
por: Liu, Shi-lei, et al.
Publicado: (2022)

Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer)
por: Sikander, Mohammed, et al.
Publicado: (2019)

Inferring biochemical reaction pathways: the case of the gemcitabine pharmacokinetics
por: Lecca, Paola, et al.
Publicado: (2012)

Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment
por: Tosca, Elena M., et al.
Publicado: (2023)

A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory
por: De Carlo, Alessandro, et al.
Publicado: (2023)

Coix Seed Extract Enhances the Anti-Pancreatic Cancer Efficacy of Gemcitabine through Regulating ABCB1- and ABCG2-Mediated Drug Efflux: A Bioluminescent Pharmacokinetic and Pharmacodynamic Study
por: Qian, Yifan, et al.
Publicado: (2019)

The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer
por: Florio, Rosalba, et al.
Publicado: (2019)

Inter-compound and Intra-compound Global Sensitivity Analysis of a Physiological Model for Pulmonary Absorption of Inhaled Compounds
por: Melillo, Nicola, et al.
Publicado: (2020)

A mechanistic framework for a priori pharmacokinetic predictions of orally inhaled drugs
por: Hartung, Niklas, et al.
Publicado: (2020)

Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent
por: Dovizio, Melania, et al.
Publicado: (2012)

Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects
por: Ahmed, Salman, et al.
Publicado: (2020)

A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis
por: Ribba, B, et al.
Publicado: (2014)

Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics
por: Cheng, Yung-Yi, et al.
Publicado: (2018)

Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1
por: Akashi, Y, et al.
Publicado: (2014)

Anticancer effect of locally applicable aptamer‐conjugated gemcitabine‐loaded atelocollagen patch in pancreatic cancer patient–derived xenograft models
por: Hong, Seung Soo, et al.
Publicado: (2022)

Histidine Enhances the Anticancer Effect of Gemcitabine against Pancreatic Cancer via Disruption of Amino Acid Homeostasis and Oxidant—Antioxidant Balance
por: Kumar, Narendra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iq2k1h76mtgaju4hti3obqhabn